Pluristem Therapeutics Net Income 2006-2021 | PSTI

Pluristem Therapeutics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Pluristem Therapeutics Annual Net Income
(Millions of US $)
2021 $-50
2020 $-29
2019 $-35
2018 $-26
2017 $-28
2016 $-23
2015 $-25
2014 $-27
2013 $-21
2012 $-15
2011 $-11
2010 $-7
2009 $-7
2008 $-10
2007 $-8
2006 $-2
2005 $-2
Pluristem Therapeutics Quarterly Net Income
(Millions of US $)
2021-09-30 $-11
2021-06-30 $-15
2021-03-31 $-14
2020-12-31 $-13
2020-09-30 $-8
2020-06-30 $-8
2020-03-31 $-8
2019-12-31 $-6
2019-09-30 $-7
2019-06-30 $-8
2019-03-31 $-10
2018-12-31 $-9
2018-09-30 $-9
2018-06-30 $-9
2018-03-31 $-2
2017-12-31 $-8
2017-09-30 $-7
2017-06-30 $-7
2017-03-31 $-8
2016-12-31 $-7
2016-09-30 $-6
2016-06-30 $-6
2016-03-31 $-7
2015-12-31 $-4
2015-09-30 $-6
2015-06-30 $-5
2015-03-31 $-7
2014-12-31 $-6
2014-09-30 $-6
2014-06-30 $-6
2014-03-31 $-9
2013-12-31 $-7
2013-09-30 $-5
2013-06-30 $-7
2013-03-31 $-6
2012-12-31 $-4
2012-09-30 $-4
2012-06-30 $-4
2012-03-31 $-4
2011-12-31 $-2
2011-09-30 $-4
2011-06-30 $-4
2011-03-31 $-3
2010-12-31 $-3
2010-09-30 $-2
2010-06-30 $-2
2010-03-31 $-2
2009-12-31 $-2
2009-09-30 $-2
2009-06-30 $-2
2009-03-31 $-2
2008-12-31 $-1
2008-09-30 $-2
2008-06-30 $-3
2008-03-31 $-3
2007-12-31 $-3
2007-09-30 $-2
2007-06-30 $-4
2007-03-31 $-4
2006-12-31 $-1
2006-09-30 $-0
2006-06-30 $-1
2006-03-31 $-1
2005-12-31 $-0
2005-09-30 $-0
2005-06-30 $0
2005-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.062B $0.000B
PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69